Adults with type 2 diabetes and a body mass index of 35 or higher who took the highest dose of retatrutide lost an average of 23.4% of their body weight, about 60.8 pounds, over 80 weeks. The figure comes from the full TRIUMPH-2 results, now peer-reviewed and published in The Lancet on Sept. 29, 2026, alongside a presentation at the European Association for the Study of Diabetes meeting in Milan.
Update Note: This article reports new information involving Eli Lilly's experimental drug retatrutide following MedicalDaily's earlier coverage. (Latest verified update: Sept. 29, 2026; sources: The Lancet and Eli Lilly.)
